Bausch and Lomb Newswire (Page 3)

Bausch and Lomb Newswire (Page 3)

Comprehensive Real-Time News Feed for Bausch and Lomb. (Page 3)

Results 41 - 60 of 650 in Bausch and Lomb

  1. Lomb Memorial re-lit for first time in 30 yearsRead the original story w/Photo

    Monday May 30 | WHEC-TV Rochester

    It was first dedicated on Memorial Day in 1932 as a tribute to Captain Henry Lomb -- a Bausch and Lomb founder and a veteran.


  2. Eye Infections Treatment Market Value Share, Supply Demand 2016-2026Read the original story w/Photo

    Monday May 30 | SBWire

    There are numerous eye-infections caused by various viruses, bacteria, parasites, and fungi that can invade the human body, and also have the potential of attacking the surface or interior of the eye. Eye infections can be the inflammation of the Conjunctiva , eyelid , the cornea , the liquid inside the eye , the retina and the blood vessels that feed it , optic nerve and others.


  3. Relighting the Lomb MemorialRead the original story w/Photo

    Monday May 30 | WHEC-TV Rochester

    ... on Memorial Day. The memorial is named in honor of Veteran Henry Lomb. It hasn't been lit in over 30 years. Bausch and Lomb wanted to move the monument to Goodman Street a couple of years ago. When they found out that a city administrator wanted to ...


  4. Overnight Healthcare: IRS doubted legality of ObamaCare payments, ex-official saysRead the original story w/Photo

    May 25, 2016 | The Hill

    The IRS raised concerns in early 2014 about the legality of certain ObamaCare payments that Republicans are now challenging in a lawsuit, according to a deposition from a former agency official. David Fisher, who was the IRS's chief risk officer, told the House Ways and Means Committee that agency officials questioned whether the Affordable Care Act provided the authority to make certain payments to insurers without an appropriation from Congress.


  5. Valeant's new CEO: 'Did we do that? Yes. Was it a mistake?...Read the original story w/Photo

    May 23, 2016 | Connecticut Post

    Joseph Papa has been on the job for just three weeks, but the new CEO of Valeant Pharmaceuticals has some big questions to answer about the embattled company. Of those, a big one is whether Valeant will start to sell assets to pay down its massive debt pile.


  6. Valeant CEO Papa plans to lower debt by more than US$1.5 billion in 2016Read the original story w/Photo

    May 23, 2016 |

    Valeant Pharmaceuticals Inc plans to lower its debt by at least US$1.5 billion this year, Chief Executive Officer Joseph Papa said on Monday during his first large meeting with investors since taking the top job three weeks ago. The company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval, Quebec May 19, 2015.


  7. Valeant CEO Papa plans to lower debt by more than $1.5-billionRead the original story w/Photo

    May 23, 2016 | The Globe and Mail

    Valeant Pharmaceuticals Inc plans to lower its debt by at least $1.5-billion this year, Chief Executive Officer Joseph Papa said on Monday during his first large meeting with investors since taking the top job three weeks ago. Valeant has about $30-billion in debt and has had to appease creditors, who had the option of forcing early payment of some loans and bonds after Valeant missed deadlines for filing financial records with regulators and triggering default notices.


  8. Bausch & Lomb Wins Walmart "Supplier Of The Year" AwardRead the original story

    May 22, 2016 | BioSpace

    Bausch + Lomb, which includes the Valeant Consumer Healthcare portfolio and businesses, is the largest global provider of eye care products. The award, which was presented at Walmart's annual supplier summit, recognized Valeant's significant current and long-term investment plans in its U.S. manufacturing facilities specifically the Bausch + Lomb sites in "We take pride in our ability to develop and introduce products that consumers want and need, and on our speed-to-market capabilities," said , Senior Vice President and General Manager, Consumer Healthcare.


  9. Year-old society seeks to expand role in areaRead the original story

    May 13, 2016 | Rochester Business Journal

    In just over a year since its launch, the Society for Information Management's Western New York Chapter has grown to 56 members, a signal of both the current and future needs of the local information technology community. "Rochester was dominated by Kodak, Xerox and Bausch & Lomb," said John Milazzo Jr., chief information officer for Kodak Alaris Inc. and membership chairman of the local chapter.


  10. The YMCA to launch campaignRead the original story

    May 12, 2016 | Rochester Business Journal

    When officials from the YMCA of Greater Rochester and community members gather at the Maplewood branch Saturday, it will be a celebration of both an anniversary and a rebirth. The celebration also kicks off a larger effort - a $75 million capital campaign that has raised $38 million through its quiet phase for a variety of projects across Monroe County.


  11. 9 Reasons Why the Worst May Not Be Over for Valeant PharmaceuticalsRead the original story w/Photo

    May 19, 2016 | Fox News

    Someone call Doc Emmett Brown from Back to the Future , because Valeant Pharmaceuticals shareholders would sure like to go back to August 2015, when their stock was valued at roughly $90 billion and trading above $260 per share. With Valeant's stock price falling once more on Thursday, and touching a fresh 52-week low, Valeant's market cap now stands at just $8.5 billion.


  12. Sentiment Has Shifted For ValeantRead the original story w/Photo

    May 18, 2016 | Seeking Alpha

    ... is getting less negative on Valeant is last Friday's rumor that KKR submitted a ~$22 billion bid for the Bausch and Lomb portfolio. Though the bid makes no sense - KKR would pay three times what Valeant paid for it - markets are warming up to ...


  13. Valeant's thinking about shedding some assetsRead the original story w/Photo

    May 17, 2016 | Silicon Alley Insider

    Valeant Pharmaceuticals is thinking about selling some of its skin and cancer drugs in order to pay down some of its over $30 billion debt pile, according to Manuel Baigorri, Ed Hammond and Cynthia Koons at Bloomberg. Valeant started to unravel in October, when allegations of malfeasance from a short seller combined with government scrutiny over its pricing practices to drag the stock down.


  14. When To Buy ValeantRead the original story w/Photo

    May 16, 2016 | Seeking Alpha

    It is difficult to know exactly when the company becomes undervalued because of its massive debt load, but if the sell-off continues, VRX is a buy. Buying bad news is one of the best ways to make money in the stock market.


  15. 'Transfer of Flags' Ceremony Honors Students for Academic Achievement and CitizenshipRead the original story w/Photo

    May 15, 2016 | Your News Now

    ... school." The first "Transfer of Flags" ceremony was proposed by Captain Henry Lomb, one of the founders of Bausch and Lomb. Access to our on-demand video clips is now open to all users. However, full shows and archive clips are limited to TWC video ...


  16. Joshua Toth, Scholastic SuperstarRead the original story

    May 14, 2016 | The Times-Tribune

    ... Joshua received high honors for his entire high school career. He is an AP Scholar with distinction, won the Bausch and Lomb science award. He participated in the Congress for Future Medical Leaders in Washington, D.C., and the Congress of ...


  17. Bausch and Lomb collaborates with IBM for an app to help cataract surgeons work betterRead the original story

    May 11, 2016 | New Launches

    Bausch + Lomb, a leading global eye health company, and IBM today announced a collaboration to develop the first app of its kind for iPhone and iPad for surgeons who perform cataract surgery. The innovative app will help surgeons streamline their workflow by delivering patient information and clinical insights as well as intraocular lens options on a single, digital platform at the point of care.


  18. Ackman after Valeant to float B&LRead the original story w/Photo

    May 10, 2016 | Seeking Alpha

    Hedge fund investor and major shareholder Bill Ackman is urging Valeant Pharmaceuticals to IPO subsidiary Bausch & Lomb as one way to unlock value in the firm and raise capital. He voiced his opinion to then-CEO Michael Pearson in a March 3 email that was part of the Senate's 818-page document published after its hearings on drug pricing.


  19. Oil Falls, Stocks Go Nowhere: Here's what you need to know...Read the original story w/Photo

    May 9, 2016 | Connecticut Post

    The decline in oil prices came after news out this weekend that Saudi Arabia would replace its oil minister after 20 years on the job. On Monday, the European investment company announced a deal to acquire Krispy Kreme for $1.35 billion, or $21 per share.


  20. Valeant vows to report its results ahead of deadlineRead the original story

    May 9, 2016 | Rochester Business Journal

    Bausch & Lomb Inc. parent Valeant Pharmaceuticals International Inc. will file its first-quarter report early, Valeant officials said Monday. The Canada-based pharmaceutical firm promised to file its report no later than June 10. That is a full month ahead of the July 31 deadline set by Valeant's bondholders.